Inventor · disambiguated record
Volker Knappertz
Also filed as: KNAPPERTZ VOLKER · KNAPPERTZ VOLKER ARMIN
12 granted patents·36 pending applications·185 citations·filing 2013–2025
91Inventor score
Files withGW RES LTD27KNAPPERTZ VOLKER9JAZZ PHARMACEUTICALS RESEARCH UK LTD6GW PHARMA LTD2TARCIC NORA2
Top patents by PatentIndex Score
48 records- 0198US11590087B2Cannabidiol-type cannabinoid compoundGW RES LTD·Filed 2022·Granted Feb 28, 2023·23 cites·20 claims
- 0297US11406623B2Methods of treating tuberous sclerosis complex with cannabidiol and everolimusGW RES LTD·Filed 2021·Granted Aug 9, 2022·24 cites·25 claims
- 0397US11160795B2Methods of treating tuberous sclerosis complex with cannabidiol and everolimusGW RES LTD·Filed 2021·Granted Nov 2, 2021·38 cites·29 claims
- 0496US12102619B2Methods of treating tuberous sclerosis complex with cannabidiol and everolimusJAZZ PHARMACEUTICALS RESEARCH UK LTD·Filed 2022·Granted Oct 1, 2024·7 cites·24 claims
- 0596US11865102B2Cannabidiol preparations and its usesGW RES LTD·Filed 2021·Granted Jan 9, 2024·18 cites·30 claims
- 0696US11419829B2Use of cannabidiol in combination with 5-HT2B receptor agonists or amphetamines in the treatment of epilepsyGW RES LTD·Filed 2018·Granted Aug 23, 2022·23 cites·17 claims
- 0796US11207292B2Cannabidiol preparations and its usesGW RES LTD·Filed 2020·Granted Dec 28, 2021·47 cites·26 claims
- 0886US12396963B2Cannabidiol-type cannabinoid compoundJAZZ PHARMACEUTICALS RESEARCH UK LTD·Filed 2020·Granted Aug 26, 2025·1 cites·7 claims
- 0986US12364670B2Cannabidiol-type cannabinoid compoundJAZZ PHARMACEUTICALS RESEARCH UK LTD·Filed 2020·Granted Jul 22, 2025·1 cites·11 claims
- 1085US12383512B2Cannabidiol-type cannabinoid compoundJAZZ PHARMACEUTICALS RESEARCH UK LTD·Filed 2020·Granted Aug 12, 2025·1 cites·10 claims
- 1182US12383567B2Use of cannabinoids in the treatment of epilepsyJAZZ PHARMACEUTICALS RESEARCH UK LTD·Filed 2018·Granted Aug 12, 2025·1 cites·12 claims
- 1279US2024207220A1Cannabidiol preparations and its usesGW RES LTD·Filed 2023·Application pending·0 cites
- 1377US2025177321A1Use of cannabinoids in the treatment of epilepsyGW RES LTD·Filed 2024·Application pending·0 cites
- 1470US2021052512A1Cannabidiol preparations and its usesGW RES LTD·Filed 2019·Application pending·0 cites
- 1568US2025381152A1Cannabidiol-type cannabinoid compoundJAZZ PHARMACEUTICALS RESEARCH UK LTD·Filed 2025·Application pending·0 cites
- 1666US9662322B2Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability statusKNAPPERTZ VOLKER·Filed 2015·Granted May 30, 2017·1 cites·28 claims
- 1764US2023143812A1Use of cannabinoids in the treatment of epilepsyGW RES LTD·Filed 2022·Application pending·0 cites
- 1862US2020352878A1Use of cannabinoids in the treatment of epilepsyGW PHARMA LTD·Filed 2019·Application pending·0 cites
- 1961US2022087951A1Use of cannabinoids in the treatment of epilepsyGW RES LTD·Filed 2020·Application pending·0 cites
- 2061US2025025482A1Use of cannabidiol in the treatment of epilepsyGW RES LTD·Filed 2022·Application pending·0 cites
- 2159US2022023232A1Use of cannabinoids in the treatment of epilepsyGW RES LTD·Filed 2020·Application pending·0 cites
- 2257US2016184428A1Treatment of multiple sclerosis by alemtuzumab induction followed by laquinimod therapyKNAPPERTZ VOLKER·Filed 2014·Application pending·0 cites
- 2355US2022008355A1Use of cannabinolids in the treatment of epilepsyGW RES LTD·Filed 2019·Application pending·0 cites
- 2454US2024091241A1Use of cannabidiol preparations in the treatment of temporal lobe epilepsyGW RES LTD·Filed 2020·Application pending·0 cites
- 2552US2024016819A1Cannabinoids for use in the treatment of epilepsyGW RES LTD·Filed 2021·Application pending·0 cites
- 2652US2022378738A1(+)-trans tetrahydrocannabinol ((+)-trans-thc) for use as a medicamentGW RES LTD·Filed 2020·Application pending·0 cites
- 2752US2022378715A1Use of cannabidiol preparations in the treatment of absence epilepsyGW RES LTD·Filed 2020·Application pending·0 cites
- 2852US2022387377A1(+)-cis tetrahydrocannabinol ((+)-cis-thc) for use as a medicamentGW RES LTD·Filed 2020·Application pending·0 cites
- 2952US2022387350A1Cannabidivarin preparations for use as a medicamentGW RES LTD·Filed 2020·Application pending·0 cites
- 3052US2022380334A1(-) - cis tetrahydrocannabinol ((-) - cis-thc) for use as a medicamentGW RES LTD·Filed 2020·Application pending·0 cites
- 3152US2022378714A1Use of cannabidiol preparations in the treatment of fragile x syndromeGW RES LTD·Filed 2020·Application pending·0 cites
- 3251US2021169824A1Use of cannabinoids in the treatment of seizures as associated with lennox-gastaut syndromeGW RES LTD·Filed 2018·Application pending·0 cites
- 3351US2022226257A1Use of cannabinoids in the treatment of comorbidities associated with epilepsyGW RES LTD·Filed 2020·Application pending·0 cites
- 3451US2022183997A1Use of cannabidiol in combination with antibioticsGW PHARMA LTD·Filed 2020·Application pending·0 cites
- 3551US2022257529A1Use of cannabidiol in the treatment of epileptic spasmsGW RES LTD·Filed 2020·Application pending·0 cites
- 3651US2022016048A1Cannabidiol-type cannabinoid compoundGW RES LTD·Filed 2019·Application pending·0 cites
- 3750US2025319107A1Use of cannabidiol and clobazam in the treatment of childhood-onset epilepsy syndromesGW RES LTD·Filed 2022·Application pending·0 cites
- 3850US2015094332A1Laquinimod Combination Therapy For Treatment Of Multiple SclerosisKNAPPERTZ VOLKER·Filed 2014·Application pending·0 cites
- 3947US2016296513A1Treatment of multiple sclerosis by alemtuzumab induction followed by laquinimod therapyKNAPPERTZ VOLKER·Filed 2016·Application pending·0 cites
- 4045US2017304253A1Laquinimod Combination Therapy For Treatment Of Multiple SclerosisKNAPPERTZ VOLKER·Filed 2017·Application pending·0 cites
- 4145US2017151224A1Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability statusKNAPPERTZ VOLKER·Filed 2017·Application pending·0 cites
- 4243US2014235670A1Treatment of progressive forms of multiple sclerosis with laquinimodTARCIC NORA·Filed 2014·Application pending·0 cites
- 4342US2016271094A1Laquinimod Combination Therapy For Treatment Of Multiple SclerosisKNAPPERTZ VOLKER·Filed 2016·Application pending·0 cites
- 4442US2015044168A1Treatment of Multiple Sclerosis With Anti-CD19 AntibodyMEDIMMUNE LLC·Filed 2013·Application pending·0 cites
- 4540US2016317525A1Treatment of multiple sclerosis with combination of laquinimod and teriflunomideKNAPPERTZ VOLKER·Filed 2014·Application pending·0 cites
- 4640US2015306088A1Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability statusKNAPPERTZ VOLKER·Filed 2015·Application pending·0 cites
- 4740US2018064702A1Treatment of progressive forms of multiple sclerosis with laquinimodTARCIC NORA·Filed 2017·Application pending·0 cites
- 4832US2018250284A1Quinoline derivatives for use in treating leukodystrophy and treatment methodGEORG AUGUST UNIV GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS UNIVSMEDIZIN·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Volker Knappertz files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →